William Stohl, MD, PhD

Professor of Medicine

Chief, Division of Rheumatology

Is this your profile? Click to edit

Overview

Dr. Stohl’s research focus is on systemic lupus erythematosus (pathogenesis, natural course of disease, treatment, animal models, immunologic disturbances, novel therapeutics); rheumatoid arthritis (pathogenesis, natural course of disease, treatment, animal models, immunologic disturbances, novel therapeutics); Sjogren’s syndrome (biomarkers, novel therapeutics); and B cells (basic biology, role in autoimmune diseases, development of targeted therapies).

Dr. Stohl received his M.D. (1977) and his Ph.D. (1979) from the University Pennsylvania.

Awards

Arthritis Foundation Southern California Chapter: James R. Klinenberg, M.D. Award, 2003
University of Pennsylvania School of Medicine: Upjohn Award, 1979

Publications

Innate and adaptive immune cell interaction drives inflammasome activation and hepatocyte apoptosis in murine liver injury from immune checkpoint inhibitors Cell Death Dis. 2024 Feb 14; 15(2):140. . View in PubMed
Industry Payments to United States Rheumatologist-Authors of Publications in High-Impact Rheumatology Journals ACR Open Rheumatol. 2023 Nov; 5(11):609-618. . View in PubMed
Impaired dynamic X-chromosome inactivation maintenance in T cells is a feature of spontaneous murine SLE that is exacerbated in female-biased models J Autoimmun. 2023 09; 139:103084. . View in PubMed
Maternal and cord blood BAFF and APRIL levels during pregnancy Am J Reprod Immunol. 2023 03; 89(3):e13654. . View in PubMed
Belimumab for the treatment of pediatric patients with lupus nephritis Expert Opin Biol Ther. 2023 03; 23(3):243-251. . View in PubMed
Isoform-specific knockdown of long and intermediate prolactin receptors interferes with evolution of B-cell neoplasms Commun Biol. 2023 03 20; 6(1):295. . View in PubMed
Impact of Belimumab on Organ Damage in Systemic Lupus Erythematosus Arthritis Care Res (Hoboken). 2022 Nov; 74(11):1822-1828. . View in PubMed
Reductions in circulating B cell subsets and immunoglobulin G levels with long-term belimumab treatment in patients with SLE Lupus Sci Med. 2022 02; 9(1). . View in PubMed
Preferential Expansion of Foxp3+ T Regulatory Cells in CTLA-4-Deficient and CTLA-4-Haploinsufficient C57BL/6 Mice Immunohorizons. 2022 07 25; 6(7):507-514. . View in PubMed
B Cell and T Cell Dissimilarities in BAFF-Deficient versus BR3-Deficient C57BL/6 Mice J Immunol. 2022 12 01; 209(11):2133-2140. . View in PubMed
Novel signatures associated with systemic lupus erythematosus clinical response to IFN-a/-? inhibition. Lupus. 2021 Apr; 30(5):795-806.. View in PubMed
Mortality and adverse events of special interest with intravenous belimumab for adults with active, autoantibody-positive systemic lupus erythematosus (BASE): a multicentre, double-blind, randomised, placebo-controlled, phase 4 trial Lancet Rheumatol. 2021 Feb; 3(2):e122-e130. . View in PubMed
First-trimester serum BAFF:sFlt-1 ratio as a candidate early biomarker of spontaneous abortion Am J Reprod Immunol. 2021 10; 86(4):e13428. . View in PubMed
Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: the phase 3, randomised controlled FINCH 3 trial Ann Rheum Dis. 2021 06; 80(6):727-738. . View in PubMed
J Transl Autoimmun. 2021; 4:100075. . View in PubMed
First-in-Human study of JNJ-55920839 in healthy volunteers and patients with systemic lupus erythematosus: a randomised placebo-controlled phase 1 trial Lancet Rheumatol. 2020 Oct; 2(10):e613-e622. . View in PubMed
Systemic lupus erythematosus (SLE): emerging therapeutic targets Expert Opin Ther Targets. 2020 12; 24(12):1283-1302. . View in PubMed
Development of Murine Systemic Lupus Erythematosus in the Absence of BAFF Arthritis Rheumatol. 2020 02; 72(2):292-302. . View in PubMed
Promotion of T Regulatory Cells in Mice by B Cells and BAFF J Immunol. 2020 05 01; 204(9):2416-2428. . View in PubMed
Circulating TNF-like protein 1A (TL1A) is elevated early in rheumatoid arthritis and depends on TNF Arthritis Res Ther. 2020 05 07; 22(1):106. . View in PubMed
Belimumab and Rituximab in Systemic Lupus Erythematosus: A Tale of Two B Cell-Targeting Agents Front Med (Lausanne). 2020; 7:303. . View in PubMed
The safety of belimumab for the treatment of systemic lupus erythematosus Expert Opin Drug Saf. 2019 Dec; 18(12):1133-1144. . View in PubMed
Elevated serum globulin gap as a highly reliable marker of elevated erythrocyte sedimentation rate in patients with systemic rheumatic diseases Semin Arthritis Rheum. 2019 12; 49(3):485-492. . View in PubMed
IgM Plasma Cells Reside in Healthy Skin and Accumulate with Chronic Inflammation J Invest Dermatol. 2019 12; 139(12):2477-2487. . View in PubMed
Safety and Efficacy of Belimumab Plus Standard Therapy for Up to Thirteen Years in Patients With Systemic Lupus Erythematosus Arthritis Rheumatol. 2019 07; 71(7):1125-1134. . View in PubMed
Constitutive reduction in the checkpoint inhibitor, CTLA-4, does not accelerate SLE in NZM 2328 mice Lupus Sci Med. 2019; 6(1):e000313. . View in PubMed
A 6-month open-label extension study of the safety and efficacy of subcutaneous belimumab in patients with systemic lupus erythematosus Lupus. 2018 Aug; 27(9):1489-1498. . View in PubMed
Efficacy and Safety of Subcutaneous Belimumab in Anti-Double-Stranded DNA-Positive, Hypocomplementemic Patients With Systemic Lupus Erythematosus Arthritis Rheumatol. 2018 08; 70(8):1256-1264. . View in PubMed
Increased Cathepsin S activity associated with decreased protease inhibitory capacity contributes to altered tear proteins in Sjögren’s Syndrome patients Sci Rep. 2018 07 23; 8(1):11044. . View in PubMed
Clinical response beyond the Systemic Lupus Erythematosus Responder Index: post-hoc analysis of the BLISS-SC study Lupus Sci Med. 2018; 5(1):e000288. . View in PubMed
A TLR9-dependent checkpoint governs B cell responses to DNA-containing antigens J Clin Invest. 2017 May 01; 127(5):1651-1663. . View in PubMed
Serum progranulin levels in Hispanic rheumatoid arthritis patients treated with TNF antagonists: a prospective, observational study Clin Rheumatol. 2017 Mar; 36(3):507-516. . View in PubMed
Maternal Serum B-Cell Activating Factor Levels: Candidate Early Biomarker for Hypertensive Disorders of Pregnancy Hypertension. 2017 11; 70(5):1007-1013. . View in PubMed
Systemic lupus erythematosus: BAFF emerges from the genetic shadows Nat Rev Rheumatol. 2017 08; 13(8):456-457. . View in PubMed
Inhibition of B cell activating factor (BAFF) in the management of systemic lupus erythematosus (SLE) Expert Rev Clin Immunol. 2017 06; 13(6):623-633. . View in PubMed
Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus: A Fifty-Two-Week Randomized, Double-Blind, Placebo-Controlled Study Arthritis Rheumatol. 2017 05; 69(5):1016-1027. . View in PubMed
B cell-independent contribution of BAFF to murine autoimmune disease Clin Immunol. 2016 Nov; 172:111-116. . View in PubMed
Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study Ann Rheum Dis. 2016 Feb; 75(2):332-40. . View in PubMed
Differential Development of Systemic Lupus Erythematosus in NZM 2328 Mice Deficient in Discrete Pairs of BAFF Receptors Arthritis Rheumatol. 2015 Sep; 67(9):2523-35. . View in PubMed
Treatment of systemic lupus erythematosus patients with the BAFF antagonist “peptibody” blisibimod (AMG 623/A-623): results from randomized, double-blind phase 1a and phase 1b trials Arthritis Res Ther. 2015 Aug 20; 17:215. . View in PubMed
A dendritic-cell-stromal axis maintains immune responses in lymph nodes Immunity. 2015 Apr 21; 42(4):719-30. . View in PubMed
Editorial: the BAFFling immunology of systemic lupus erythematosus: beyond B cells Arthritis Rheumatol. 2015 Mar; 67(3):612-5. . View in PubMed
APRIL mediates peritoneal B-1 cell homeostasis Immunol Lett. 2014 Aug; 160(2):120-7. . View in PubMed
Tear cathepsin S as a candidate biomarker for Sjögren’s syndrome Arthritis Rheumatol. 2014 Jul; 66(7):1872-81. . View in PubMed
Arthritis Rheumatol. 2014 May; 66(5):1153-64. . View in PubMed
Therapeutic targeting of the BAFF/APRIL axis in systemic lupus erythematosus Expert Opin Ther Targets. 2014 Apr; 18(4):473-89. . View in PubMed
Lloyd Mayer, MD, 1952-2013, In Memoriam Clin Immunol. 2014 Feb; 150(2):A1-A2. . View in PubMed
Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus J Rheumatol. 2014 Feb; 41(2):300-9. . View in PubMed
Local BLyS production by T follicular cells mediates retention of high affinity B cells during affinity maturation J Exp Med. 2014 Jan 13; 211(1):45-56. . View in PubMed
Future prospects in biologic therapy for systemic lupus erythematosus Nat Rev Rheumatol. 2013 Dec; 9(12):705-20. . View in PubMed
BAFF- and APRIL-dependent maintenance of antibody titers after immunization with T-dependent antigen and CD1d-binding ligand J Immunol. 2013 Aug 01; 191(3):1154-63. . View in PubMed
Incremental expenditure of biologic disease modifying antirheumatic treatment using instrumental variables in panel data Health Econ. 2013 Jul; 22(7):807-23. . View in PubMed
Efficacy and safety of belimumab in patients with rheumatoid arthritis: a phase II, randomized, double-blind, placebo-controlled, dose-ranging Study J Rheumatol. 2013 May; 40(5):579-89. . View in PubMed
Development of systemic lupus erythematosus in NZM 2328 mice in the absence of any single BAFF receptor Arthritis Rheum. 2013 Apr; 65(4):1043-54. . View in PubMed
Racial/ethnic differences in the use of biologic disease-modifying antirheumatic drugs among California Medicaid rheumatoid arthritis patients Arthritis Care Res (Hoboken). 2013 Feb; 65(2):299-303. . View in PubMed
Induced T regulatory cells suppress osteoclastogenesis and bone erosion in collagen-induced arthritis better than natural T regulatory cells Ann Rheum Dis. 2012 Sep; 71(9):1567-1572. . View in PubMed
Biologic differences between various inhibitors of the BLyS/BAFF pathway: should we expect differences between belimumab and other inhibitors in development? Curr Rheumatol Rep. 2012 Aug; 14(4):303-9.. View in PubMed
Effect of belimumab on vaccine antigen antibodies to influenza, pneumococcal, and tetanus vaccines in patients with systemic lupus erythematosus in the BLISS-76 trial J Rheumatol. 2012 Aug; 39(8):1632-40. . View in PubMed
Safety and efficacy of ocrelizumab in combination with methotrexate in MTX-naive subjects with rheumatoid arthritis: the phase III FILM trial Ann Rheum Dis. 2012 Aug; 71(8):1289-96. . View in PubMed
Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus Arthritis Rheum. 2012 Jul; 64(7):2328-37. . View in PubMed
Dispensability of APRIL to the development of systemic lupus erythematosus in NZM 2328 mice Arthritis Rheum. 2012 May; 64(5):1610-9. . View in PubMed
Sustained inhibition of progressive joint damage with rituximab plus methotrexate in early active rheumatoid arthritis: 2-year results from the randomised controlled trial IMAGE Ann Rheum Dis. 2012 Mar; 71(3):351-7. . View in PubMed
The discovery and development of belimumab: the anti-BLyS-lupus connection Nat Biotechnol. 2012 Jan 09; 30(1):69-77. . View in PubMed
A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus Arthritis Rheum. 2011 Dec; 63(12):3918-30. . View in PubMed
Cytokine disturbances in systemic lupus erythematosus Arthritis Res Ther. 2011 Jul 06; 13(4):228. . View in PubMed
Targeting BLyS in rheumatic disease: the sometimes-bumpy road from bench to bedside Curr Opin Rheumatol. 2011 May; 23(3):305-10. . View in PubMed
B Cell and BAFF dependence of IFN-a-exaggerated disease in systemic lupus erythematosus-prone NZM 2328 mice J Immunol. 2011 Apr 15; 186(8):4984-93. . View in PubMed
J Immunol. 2011 Apr 01; 186(7):4223-33. . View in PubMed
Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial Ann Rheum Dis. 2011 Jan; 70(1):39-46. . View in PubMed
BAFF promotes Th17 cells and aggravates experimental autoimmune encephalomyelitis PLoS One. 2011; 6(8):e23629. . View in PubMed
Constitutive overexpression of BAFF in autoimmune-resistant mice drives only some aspects of systemic lupus erythematosus-like autoimmunity Arthritis Rheum. 2010 Aug; 62(8):2432-42. . View in PubMed
Association of the response to tumor necrosis factor antagonists with plasma type I interferon activity and interferon-beta/alpha ratios in rheumatoid arthritis patients: a post hoc analysis of a predominantly Hispanic cohort Arthritis Rheum. 2010 Feb; 62(2):392-401. . View in PubMed
Autoantibody-dependent and autoantibody-independent roles for B cells in systemic lupus erythematosus: past, present, and future Autoimmunity. 2010 Feb; 43(1):84-97. . View in PubMed
Systemic lupus erythematosus and its ABCs (APRIL/BLyS complexes) Arthritis Res Ther. 2010; 12(2):111. . View in PubMed
B lymphocyte stimulator expression in pediatric systemic lupus erythematosus and juvenile idiopathic arthritis patients Arthritis Rheum. 2009 Nov; 60(11):3400-9. . View in PubMed
Elevated synovial expression of triggering receptor expressed on myeloid cells 1 in patients with septic arthritis or rheumatoid arthritis Ann Rheum Dis. 2009 Nov; 68(11):1768-74. . View in PubMed
Deficiency of type I IFN receptor in lupus-prone New Zealand mixed 2328 mice decreases dendritic cell numbers and activation and protects from disease J Immunol. 2009 Nov 01; 183(9):6021-9. . View in PubMed
Novel evidence-based systemic lupus erythematosus responder index Arthritis Rheum. 2009 Sep 15; 61(9):1143-51. . View in PubMed
A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus Arthritis Rheum. 2009 Sep 15; 61(9):1168-78. . View in PubMed
Accelerated pathological and clinical nephritis in systemic lupus erythematosus-prone New Zealand Mixed 2328 mice doubly deficient in TNF receptor 1 and TNF receptor 2 via a Th17-associated pathway J Immunol. 2009 Feb 15; 182(4):2532-41. . View in PubMed
Urinary TWEAK as a biomarker of lupus nephritis: a multicenter cohort study Arthritis Res Ther. 2009; 11(5):R143. . View in PubMed
B lymphocyte stimulator expression in patients with rheumatoid arthritis treated with tumour necrosis factor alpha antagonists: differential effects between good and poor clinical responders Ann Rheum Dis. 2008 Aug; 67(8):1132-8. . View in PubMed
Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus Arthritis Rheum. 2008 Aug; 58(8):2453-9. . View in PubMed
B cell depletion therapy in systemic lupus erythematosus: relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response Ann Rheum Dis. 2008 Jul; 67(7):1011-6. . View in PubMed
Global T cell dysregulation in non-autoimmune-prone mice promotes rapid development of BAFF-independent, systemic lupus erythematosus-like autoimmunity J Immunol. 2008 Jul 01; 181(1):833-41. . View in PubMed
Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus Arthritis Res Ther. 2008; 10(5):R109. . View in PubMed
New and promising treatments for rheumatoid arthritis Am J Orthop (Belle Mead NJ). 2007 Jul; 36(7 Suppl):18-23. . View in PubMed
Therapeutic targeting of B lymphocyte stimulator (BLyS) in the rheumatic diseases Endocr Metab Immune Disord Drug Targets. 2006 Dec; 6(4):351-8. . View in PubMed
Patients with inflammatory arthritic diseases harbor elevated serum and synovial fluid levels of free and immune-complexed glucose-6-phosphate isomerase (G6PI) Biochem Biophys Res Commun. 2006 Oct 20; 349(2):838-45. . View in PubMed
B cell depletion therapy in systemic rheumatic diseases: different strokes for different folks? Clin Immunol. 2006 Oct; 121(1):1-12.. View in PubMed
Paucity of clinical disease despite serological autoimmunity and kidney pathology in lupus-prone New Zealand mixed 2328 mice deficient in BAFF J Immunol. 2006 Aug 15; 177(4):2671-80. . View in PubMed
TGF-beta requires CTLA-4 early after T cell activation to induce FoxP3 and generate adaptive CD4+CD25+ regulatory cells J Immunol. 2006 Mar 15; 176(6):3321-9. . View in PubMed
Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse Arthritis Rheum. 2006 Mar; 54(3):723-32. . View in PubMed
B lymphocyte stimulator (BLyS) isoforms in systemic lupus erythematosus: disease activity correlates better with blood leukocyte BLyS mRNA levels than with plasma BLyS protein levels Arthritis Res Ther. 2006; 8(1):R6. . View in PubMed
Humoral autoimmunity in mice overexpressing B cell surface CD19: vital role for MHC class II Clin Immunol. 2005 Sep; 116(3):257-64. . View in PubMed
BAFF overexpression and accelerated glomerular disease in mice with an incomplete genetic predisposition to systemic lupus erythematosus Arthritis Rheum. 2005 Jul; 52(7):2080-91. . View in PubMed
Raised levels of anti-glucose-6-phosphate isomerase IgG in serum and synovial fluid from patients with inflammatory arthritis Ann Rheum Dis. 2005 May; 64(5):743-9. . View in PubMed
BlySfulness does not equal blissfulness in systemic lupus erythematosus: a therapeutic role for BLyS antagonists Curr Dir Autoimmun. 2005; 8:289-304. . View in PubMed
Increased CXCL8 (IL-8) expression in Multiple Sclerosis J Neuroimmunol. 2004 Oct; 155(1-2):161-71. . View in PubMed
Inverse association between circulating APRIL levels and serological and clinical disease activity in patients with systemic lupus erythematosus Ann Rheum Dis. 2004 Sep; 63(9):1096-103. . View in PubMed
MHC class II-independent and -dependent T cell expansion and B cell hyperactivity in vivo in mice deficient in CD152 (CTLA-4) Int Immunol. 2004 Jul; 16(7):895-904. . View in PubMed
Dichotomous effects of complete versus partial class II major histocompatibility complex deficiency on circulating autoantibody levels in autoimmune-prone mice Arthritis Rheum. 2004 Jul; 50(7):2227-39. . View in PubMed
Targeting B lymphocyte stimulator in systemic lupus erythematosus and other autoimmune rheumatic disorders Expert Opin Ther Targets. 2004 Jun; 8(3):177-89. . View in PubMed
A therapeutic role for BLyS antagonists Lupus. 2004; 13(5):317-22. . View in PubMed
B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations Arthritis Rheum. 2003 Dec; 48(12):3475-86. . View in PubMed
In vitro and in vivo T cell oligoclonality following chronic stimulation with staphylococcal superantigens Clin Immunol. 2003 Sep; 108(3):182-9. . View in PubMed
Local production of B lymphocyte stimulator protein and APRIL in arthritic joints of patients with inflammatory arthritis Arthritis Rheum. 2003 Apr; 48(4):982-92. . View in PubMed
SLE–systemic lupus erythematosus: a BLySful, yet BAFFling, disorder Arthritis Res Ther. 2003; 5(3):136-8. . View in PubMed
B lymphocyte stimulator protein levels in systemic lupus erythematosus and other diseases Curr Rheumatol Rep. 2002 Aug; 4(4):345-50. . View in PubMed
B lymphocyte stimulator protein-associated increase in circulating autoantibody levels may require CD4+ T cells: lessons from HIV-infected patients Clin Immunol. 2002 Aug; 104(2):115-22. . View in PubMed
Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases Arthritis Rheum. 2001 Jun; 44(6):1313-9. . View in PubMed
Promotion of activated human B cell apoptosis and inhibition of Ig production by soluble CD95 ligand: CD95-based downregulation of Ig production need not culminate in activated B cell death Cell Immunol. 2000 Jul 10; 203(1):1-11. . View in PubMed
Impaired cytotoxic T lymphocyte activity in systemic lupus erythematosus following in vitro polyclonal T cell stimulation: a contributory role for non-T cells Lupus. 1999; 8(4):293-9. . View in PubMed
Superantigen-driven, CD8+ T cell-mediated down-regulation: CD95 (Fas)-dependent down-regulation of human Ig responses despite CD95-independent killing of activated B cells J Immunol. 1998 Oct 01; 161(7):3292-8. . View in PubMed
CD95 (Fas)-based, superantigen-dependent, CD4+ T cell-mediated down-regulation of human in vitro immunoglobulin responses J Immunol. 1998 Jun 01; 160(11):5231-8. . View in PubMed
TCR AV24 gene expression in double negative T cells in systemic lupus erythematosus Lupus. 1998; 7(8):565-8. . View in PubMed
Impaired nonrestricted cytolytic activity in systemic lupus erythematosus: involvement of a pathway independent of Fas, tumor necrosis factor, and extracellular ATP that is associated with little detectable perforin Arthritis Rheum. 1997 Jun; 40(6):1130-7. . View in PubMed
Impaired recovery and cytolytic function of CD56+ T and non-T cells in systemic lupus erythematosus following in vitro polyclonal T cell stimulationStudies in unselected patients and monozygotic disease-discordant twins. Arthritis Rheum. 1996 Nov; 39(11):1840-51. . View in PubMed
Treatment of rheumatoid arthritis N Engl J Med. 1996 Sep 12; 335(11):821-2; author reply 822-3. . View in PubMed
In vitro inhibition by intravenous immunoglobulin of human T cell-dependent B cell differentiation induced by staphylococcal superantigens Clin Immunol Immunopathol. 1996 May; 79(2):122-33. . View in PubMed
Differential human T cell-dependent B cell differentiation induced by staphylococcal superantigens (SAg)Regulatory role for SAg-dependent B cell cytolysis. J Immunol. 1995 Aug 15; 155(4):1838-50. . View in PubMed
Impaired polyclonal T cell cytolytic activityA possible risk factor for systemic lupus erythematosus. Arthritis Rheum. 1995 Apr; 38(4):506-16. . View in PubMed
Enhancing effects of interleukin 2-treated peripheral blood mononuclear cells on subsequent B cell differentiation Cell Immunol. 1994 Sep; 157(2):381-92. . View in PubMed
Polyclonal in vitro T cell proliferation and T cell-dependent B cell differentiation supported by activated autologous B cells Clin Immunol Immunopathol. 1994 Jul; 72(1):44-52. . View in PubMed
Human T cell-dependent B cell differentiation induced by staphylococcal superantigens J Immunol. 1994 Jul 01; 153(1):117-27. . View in PubMed
Stimulation of human peripheral blood mononuclear cells with anti-CD3 monoclonal antibody vs IL2: disparate effects on T cell-dependent B cell differentiation despite similar effects on generation of unrestricted cytolytic activity Clin Immunol Immunopathol. 1992 Oct; 65(1):30-8. . View in PubMed
Impaired generation of polyclonal T cell-mediated cytolytic activity despite normal polyclonal T cell proliferation in systemic lupus erythematosus Clin Immunol Immunopathol. 1992 May; 63(2):163-72. . View in PubMed
Induction of human T cell proliferation by a monoclonal antibody to CD5 J Immunol. 1991 Jan 01; 146(1):47-52. . View in PubMed
Inhibition by anti-CD2 monoclonal antibodies of anti-CD3-induced T cell-dependent B cell activation Cell Immunol. 1990 Oct 15; 130(2):257-70. . View in PubMed
Differential CD3/T cell antigen receptor-mediated IL-2 production in jurkat T cellsDissociation of IL-2 response from total inositol phosphate and calcium responses. J Immunol. 1990 Aug 15; 145(4):1078-87. . View in PubMed
Generation of cytolytic activity with anti-CD3 monoclonal antibodies involves both IL-2-independent and -dependent components J Immunol. 1990 May 15; 144(10):3718-25. . View in PubMed
A novel role for accessory cells in T cell-dependent B cell differentiation Cell Immunol. 1990 May; 127(2):458-69. . View in PubMed
A functionally unique anti-CD3 monoclonal antibody cross-reactive with basal keratinocytes Cell Immunol. 1989 Jul; 121(2):247-60. . View in PubMed
Human peripheral blood T helper cell-induced B cell activation results in B cell surface expression of the CD23 (BLAST-2) antigen Cell Immunol. 1989 Jun; 121(1):99-112. . View in PubMed
Inhibitory effects of anti-CD2 monoclonal antibodies on interleukin 2 production and interleukin 2 receptor expression in anti-CD3-induced T cell activation Cell Immunol. 1989 May; 120(2):351-65. . View in PubMed
Characterization of lymphokines mediating B cell growth and differentiation from monoclonal anti-CD3 antibody-stimulated T cells J Immunol. 1989 Apr 01; 142(7):2343-51. . View in PubMed
Feedback inhibition of B cell differentiation by monomeric immunoglobulin Int Rev Immunol. 1989; 5(2):189-95. . View in PubMed
In vitro induction of T cell-dependent B cell differentiation in patients with common varied immunodeficiency Clin Immunol Immunopathol. 1988 Nov; 49(2):273-82. . View in PubMed
Differential immunomodulation by anti-CD2 monoclonal antibodies of anti-CD3-induced T cell activation: dependence upon the individual anti-CD3 monoclonal antibody used for activation Cell Immunol. 1988 Oct 01; 116(1):73-85. . View in PubMed
Inhibition of T cell-dependent human B cell proliferation and B cell differentiation by polyspecific monomeric IgG Clin Exp Immunol. 1987 Dec; 70(3):649-57. . View in PubMed
Correlation between systemic lupus erythematosus and T4 epitope phenotype Arthritis Rheum. 1987 Dec; 30(12):1412-5. . View in PubMed
Induction of T cell-dependent B cell differentiation by anti-CD3 monoclonal antibodies J Immunol. 1987 Mar 15; 138(6):1667-73. . View in PubMed
Modulation of the immune response by immunoglobulin for intravenous useII. Inhibitory effects of sera from treated patients. Clin Immunol Immunopathol. 1986 Nov; 41(2):273-80. . View in PubMed
Cellular mechanisms in the in vitro inhibition of pokeweed mitogen-induced B cell differentiation by immunoglobulin for intravenous use J Immunol. 1986 Jun 15; 136(12):4407-13. . View in PubMed
Modulation of the immune response by immunoglobulin for intravenous useI. Inhibition of pokeweed mitogen-induced B cell differentiation. Clin Exp Immunol. 1985 Oct; 62(1):200-7. . View in PubMed
Systemic lupus erythematosus with deficiency of the T4 epitope on T helper/inducer cells N Engl J Med. 1985 Jun 27; 312(26):1671-8. . View in PubMed
Heterogeneity in expression of the T4 epitope in black individuals Scand J Immunol. 1984 Sep; 20(3):273-8. . View in PubMed
Deficient OKT4 epitope on helper T cells in a patient with SLE: confusion with AIDS N Engl J Med. 1984 06 07; 310(23):1531. . View in PubMed
Detection of the precursor and effector cells of experimental allergic encephalomyelitis in the thoracic duct of the rat Cell Immunol. 1980 Sep 01; 54(2):471-7. . View in PubMed
Saturday classes and rounds N Engl J Med. 1979 May 17; 300(20):1165. . View in PubMed
A quantitative assay for experimental allergic encephalomyelitis in the rat based on permeability of spinal cords to 125I-human gamma-globulin J Immunol. 1979 Mar; 122(3):920-5. . View in PubMed
Chronic permeability of the central nervous system to mononuclear cells in experimental allergic encephalomyelitis in the Lewis rat J Immunol. 1978 Sep; 121(3):844-50. . View in PubMed
Religious objections to autopsy N Engl J Med. 1977 Oct 27; 297(17):953. . View in PubMed
Distribution of the thy-1 antigen in cellular and subcellular fractions of adult mouse brain J Immunol. 1977 Aug; 119(2):422-7. . View in PubMed

Similar People

Jacob, Chaim